Which medications are known to cause insulin resistance?

Medications That Cause Insulin Resistance

The most clinically significant medications that cause insulin resistance are glucocorticoids, nicotinic acid, atypical antipsychotics (especially clozapine, olanzapine, and quetiapine), statins, protease inhibitors, and thiazide diuretics. 1, 2

Primary Offenders by Drug Class

Glucocorticoids

• Most potent insulin resistance inducers among commonly prescribed medications
• Mechanism: Directly antagonize insulin action at peripheral tissues and increase hepatic glucose production
• Risk increases with higher doses and longer duration
• Effect is typically reversible upon discontinuation 1, 2

Atypical Antipsychotics

• Clozapine, olanzapine, and quetiapine carry the highest risk
• Mechanism: Complex—primarily induce insulin resistance, but can also impair insulin secretion
• Can precipitate ketoacidosis in susceptible individuals
• Risk is dose-dependent 2, 3, 4

Statins

• High-intensity statins (especially atorvastatin 40-80 mg) increase insulin resistance by approximately 8%
• Mechanism: Impair insulin signaling pathways while simultaneously increasing compensatory insulin secretion
• Risk is dose-dependent and increases with higher potency statins
• The cardiovascular benefits typically outweigh diabetes risk in most patients, but monitor glucose closely 5, 3, 4

Nicotinic Acid (Niacin)

• Directly impairs insulin action at the cellular level
• Effect is dose-dependent
• Particularly problematic in patients with pre-existing insulin resistance 1, 2

Protease Inhibitors and NRTIs

• Used in HIV treatment
• Mechanism: Induce insulin resistance through multiple pathways
• Effect varies by specific agent within the class 3, 4

Thiazide Diuretics

• Induce insulin resistance more frequently than other antihypertensive classes
• Mechanism: May involve hypokalemia-mediated effects on insulin secretion and action
• Beta-blockers also contribute but through different mechanisms 3, 4

Additional Medications That Impair Insulin Action

Immunosuppressants

• mTOR inhibitors (everolimus, sirolimus): Interfere with insulin signaling pathways, causing both impaired secretion and increased resistance 6, 3
• Calcineurin inhibitors (tacrolimus, cyclosporine): Primarily decrease insulin secretion but can affect insulin sensitivity 7, 3, 4

Hormonal Therapies

• Androgen blockers: Used in prostate cancer treatment
• High-dose estrogen oral contraceptives: Modern low-dose formulations have minimal effect 3, 4
• Growth hormone: Antagonizes insulin action 4

Other Notable Agents

• Beta-adrenergic stimulants: Can induce hyperglycemia and ketoacidosis
• Interferon-alpha and beta-interferon: Can cause diabetes with islet cell antibodies 1, 2, 3, 4
• Tyrosine kinase inhibitors and PI3 kinase inhibitors: Used in cancer treatment 7, 3
• Immune checkpoint inhibitors: Increasingly recognized cause 7

Critical Clinical Considerations

Risk Stratification

Patients at highest risk for drug-induced insulin resistance are those with:

• Pre-existing insulin resistance or prediabetes (A1C 5.7-6.4%)
• Obesity (BMI ≥30 kg/m²)
• Family history of type 2 diabetes
• History of gestational diabetes
• Metabolic syndrome components 1, 3, 4

Monitoring Strategy

• Check fasting glucose and A1C before initiating high-risk medications
• Monitor glucose at 4-6 weeks after starting therapy, then every 3 months for the first year
• For glucocorticoids and atypical antipsychotics: Check glucose within 1-2 weeks of initiation
• Continue surveillance throughout treatment duration 3, 4

Management Approach

When drug-induced insulin resistance is identified:

1. Assess necessity of the offending medication

   • Can it be discontinued or dose reduced?
   • Is there an alternative with lower diabetogenic potential?

2. If medication must be continued:

   • First-line treatment: Metformin (unless contraindicated by renal function or other factors)
   • Metformin addresses insulin resistance directly and does not cause hypoglycemia
   • Start 500 mg daily with meals, titrate to 1000 mg twice daily as tolerated 8, 6, 3

3. For inadequate response to metformin:

   • Add agents based on glucose severity and patient factors
   • Consider GLP-1 receptor agonists for additional insulin sensitization and weight benefits
   • SGLT2 inhibitors provide glucose-lowering independent of insulin action
   • Insulin therapy may be required for severe hyperglycemia (glucose >300 mg/dL or A1C >10%) 8, 6

4. Implement lifestyle modifications concurrently:

   • 5-10% weight loss significantly improves insulin sensitivity
   • 150 minutes weekly of moderate-intensity physical activity
   • These interventions are particularly effective for drug-induced insulin resistance 8

Important Caveats

Reversibility: Drug-induced insulin resistance is often reversible upon medication discontinuation, but this may take weeks to months. Some patients may have unmasked underlying diabetes that persists 3, 4, 9.

Dual mechanisms: Many medications affect both insulin secretion AND insulin action, making the classification complex. The clinical approach remains the same regardless of the precise mechanism 1, 2.

Polypharmacy risk: Multiple medications with modest diabetogenic effects can have additive or synergistic impacts on glucose metabolism 9.

Long-term complications: The risk of microvascular complications from drug-induced diabetes is underestimated because clinical trials are typically too short to assess these outcomes 3.